First human test of new cancer pill halted early
Disease control
Terminated
This early-stage study tested a new oral medication called BBI-825 in people with advanced solid tumors that had stopped responding to all standard treatments. The main goals were to find the safest dose and see how the body processes the drug. The study was terminated after enro…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC